We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Bariatric Surgery Indicated in Obese Patients with Type 2 Diabetes

By HospiMedica staff writers
Posted on 15 May 2008
Australian researchers reported in a study that surgery to induce weight loss is more effective in realizing the remission of diabetes than conventional weight loss therapy. More...


In an unblinded randomized trial conducted from December 2002 through December 2006 at the Center for Obesity Research and Education (CORE) of Monash University (Melbourne, Australia), Dr. John B. Dixon and colleagues recruited 60 obese patients with type 2 diabetes diagnosed within a two year period from the start of the study, and randomly assigned them into two treatment groups. The first group received conventional diabetes therapy focused on lifestyle changes and weight loss. The second group underwent laparoscopic adjustable gastric banding (LAGB) surgery (within one month of randomization) and in addition received conventional diabetes care. Patients in the surgery group had their progress reviewed every four to eight weeks and had their gastric band volume adjusted as needed.

The patients studied were between the ages of 20 and 60 (average age 47), with a body mass index (BMI) >30 and <40 kg/m2, and no evidence of renal impairment or retinopathy. Exclusions from the study were based on previous bariatric surgery, type 1 diabetes, or vascular events. Each patient was assessed by a dietitian, a general physician, and an endocrinologist.

The principal outcome measures were the remission of type 2 diabetes defined as fasting glucose levels of less than 126 mg/dL and glycated hemoglobin (HbA1c) value less than 6.2% without glycemic therapy. Other outcome measures were patient weight and metabolic syndrome components such as abdominal obesity.

Of the 60 patients enrolled in the study, 55 (92%) completed the 2-year follow-up. Diabetes remission was achieved for 22 (73%) of patients in the surgical group and for four (13%) in patients who received conventional therapy. Remission of type 2 diabetes was associated with weight loss and lower starting HbA1c levels. The surgical group achieved a mean body weight loss of 20% after two years (corresponding to a drop in BMI from 36.9 to 29.5 kg/m2), while patients receiving conventional therapy lost 1.4% of body weight (a drop in BMI from 37.1 to 36.6 kg/m2). Compared with patients in the conventional therapy group, those in the surgery group also achieved an improved lipid profile at the two-year mark with reductions in triglycerides, increased HDL cholesterol, and reductions in abdominal girth.

The authors of the study published in the January 23, 2008 issue of The Journal of the American Medical Association (JAMA), said that to their knowledge, theirs is the first study to document change in glycemic control in obese patients with diabetes following surgically induced weight loss, and added that their findings support early consideration for bariatric techniques in obese patients with type 2 diabetes. The authors concluded that the greater weight loss from bariatric surgery resulted in diabetic remission and metabolic improvements, but suggested the need for a larger, longer-term study.

Many prior significant studies on bariatric mediation of type 2 diabetes include a landmark paper published in 1992 in the journal Annals of Surgery by Walter Pories, professor of surgery and biochemistry at East Carolina University (Greenville, NC, USA), titled "Is type 2 diabetes mellitus (NIDDM) [non-insulin dependent diabetes mellitus] a surgical disease?” The paper reported the remission of diabetes after a gastric bypass procedure.

Another such study titled "Bariatric Surgery, A Systematic Review and Meta-Analysis” was published on October 14, 2004 in The Journal of the American Medical Association (JAMA) by lead author Henry Buchwald, M.D., Ph.D. of the University of Minnesota (Minneapolis, MN, USA). Prof. Buchwald and colleagues reported on the outcome of bariatric surgery on weight loss, operative mortality outcome, and four obesity related comorbidities: diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea. The study concluded that after bariatric surgery, weight loss was achieved in morbidly obese patients, and that a majority of the patients with the obesity related comorbidities experienced improvements or the complete resolution of their condition.


Related Links:
Monash University

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.